The global parenteral nutrition market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026.
Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that providing nutritional support to patients who are unable to utilize their gastrointestinal tract. It aids in preventing malnutrition and maintaining energy, hydration, and strength levels. As a result, it is widely used among patients who are suffering from cancer, Crohn’s disease, short bowel syndrome, ischemic bowel disease, and abnormal bowel function.
The rising prevalence of malnutrition, growing natality rate, and increasing premature births are among the primary factors catalyzing the demand for PN around the world. Moreover, there is a considerable rise in the number of individuals experiencing pediatric disorders, such as asthma, leukemia, tuberculosis, bronchitis, chickenpox, and anemia. This, along with the rising geriatric population, which is relatively more prone to chronic diseases, is also influencing the demand for PN products positively. Furthermore, the growing consumption of fast food has resulted in the growing instances of non-communicable diseases like hypertension, diabetes, obesity, and other metabolic disorders. This, in confluence with the rising incidences of hepatic insufficiency, renal insufficiency and protein-energy malnutrition, is increasing the consumption of amnio acid-rich and parenteral products. The market is further driven by significant improvements in the PN, such as lipid emulsions optimizations and utilization of indirect calorimetry. Some of the other factors, such as increasing expenditure on the overall development of the healthcare sector by the governing agencies and private entities of several countries and rising adoption of PN products by the healthcare sector, are anticipated to strengthen the market growth across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global parenteral nutrition market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, nutrient type and end user.
Breakup by Nutrient Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.
|Base Year of the Analysis||2020|
|Segment Coverage||Nutrient Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at